Recruiting

1470 Nm Laser

Sponsor:

Montefiore Medical Center

Code:

NCT06946550

Conditions

Scarring Alopecia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

1470nm non-ablative fractional laser

Study Details

Brief summary:

The goal of this clinical trial is to evaluate the effectiveness of a non-ablative 1470 nm laser in treating scarring alopecia in adults. The study will also investigate the biochemical molecular pathways involved in laser therapy by analyzing hair follicle gene expression before and after laser treatment.

The main questions it aims to answer are:

1. Does a non-ablative laser work to effectively treat scarring alopecia?
2. What molecular pathways are associated with the laser's effects on hair follicles in scarring alopecia?

Participants with scarring alopecia will:

  • Receive 3 laser treatments, spaced 1 month apart (Month 1, Month 2, Month 3), and attend 5 follow-up visits (Month 4, Month 6, Month 9, Month 12 and Month 15)
  • Have hair follicle samples collected via hair plucking of 10 hairs prior to the start and 1-month post-completion of laser treatments for gene expression analysis of inflammatory and fibrosis pathways implicated in scarring alopecia. Hair samples will be de-identified and kept anonymous.
  • Fill out questionnaires at each visit
  • Keep a diary of any side effects from laser treatments

Conditions

Scarring Alopecia

Study ID

NCT06946550

Start date

Dec 9, 2025

Status verified date

Dec, 2025

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Healthy males and females, at least 18 years of age at time of informed consent, seeking treatment for scarring alopecia
  • Subject must be able to read, understand, and voluntarily sign and date an IRB-approved informed consent form
  • Subjects with biopsy-proven or clinically diagnosed scarring alopecia recorded within the past 6 months. An established clinical diagnosis will be confirmed by a licensed dermatologist as in previously published hair plucking studies (eg. using trichoscopy and a positive pull test). Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months.
  • Subject agrees to not make any changes to their daily hair treatment regimen or start any medications for hair loss such as minoxidil during the study.
  • Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated throughout the follow-up period.

Exclusion Criteria:

  • Subject does not have capacity to consent to the study
  • No ethnic or racial group restrictions
  • Subject does not have scarring alopecia
  • History of intralesional steroid injections to the scalp in the last 12 months
  • Pregnant Women
  • Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject.
  • Any previous hospitalization or surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months.
  • Allergy or history of prior reaction to lidocaine
  • History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy in the prior 12 months.
  • Recent COVID-19 infection
  • History or current use of the following prescription medications:
  • Immunosuppressive medications/biologics, 6 months prior to and during the study
  • Accutane or other systemic retinoids within the past twelve months
  • Smoking or vaping in the past 12 months.
  • History of uncontrolled hyperlipidemia, uncontrolled diabetes mellitus, uncontrolled hepatitis, or uncontrolled bleeding disorders.
  • History of major depressive disorders or uncontrolled endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism.

Study Design

Enrollment

5 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Scarring alopecia

Patients with scarring alopecia will receive 3 treatments with the non-ablative Sciton HALO laser (1470nm). Each laser treatment will take approximately 10 to 15 minutes per subject.

Interventions

1470nm non-ablative fractional laser

Patients with scarring alopecia will be treated with the non-ablative Sciton HALO laser (1470nm).

Primary outcome measure

  • Clinician Global Aesthetic Improvement Scale [ Time Frame: Month 2, Month 3, Month 4, Month 6, Month 9, Month 12, Month 15 ]
  • Subject Global Aesthetic Improvement Scale [ Time Frame: Month 2, Month 3, Month 4, Month 6, Month 9, Month 12, Month 15 ]
  • Hair density [ Time Frame: Baseline/Month 1, 2, 3, 4, 6, 9, 12, 15 ]
  • Hair counts [ Time Frame: Baseline/Month 1, 2, 3, 4, 6, 9, 12, 15 ]

Central Contacts and Locations

Central contacts

Anika Jallorina, BS

618-704-8716ajallorina@montefiore.org

Locations

Montefiore Einstein Advanced Care

Recruiting

Elmsford, New York, United States, 10523

Contacts

Anika Jallorina

914-457-4130ajallorina@montefiore.org

Principal Investigator:

Kseniya Kobets, MD

More Information

Sponsor

Montefiore Medical Center

Last update posted

Dec 15, 2025

Last verified

Dec, 2025

Keywords

  • alopecia
  • laser

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-27. This information was provided to ClinicalTrials.gov by Montefiore Medical Center on 2025-12-15. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.